Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma

  • Authors:
    • Doksa Lee
    • Koichiro Wada
    • Yoshitaka Taniguchi
    • Hani Al-Shareef
    • Tomotake Masuda
    • Yu Usami
    • Tomonao Aikawa
    • Masaya Okura
    • Yoshinori Kamisaki
    • Mikihiko Kogo
  • View Affiliations

  • Published online on: January 13, 2014     https://doi.org/10.3892/or.2014.2975
  • Pages: 1116-1120
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Fatty acid binding proteins (FABPs) are a family of small and highly conserved lipid chaperone molecules with highly varied functions. Among them, fatty acid binding protein 4 (FABP4, also known as aP2) is highly expressed by adipocytes, macrophages and dendritic cells. Although the role of FABP4 in cancer is still unclear, it has been reported to be highly expressed by human tumors such as ovarian and bladder cancers. In the present study, we investigated the expression and role of FABP4 in oral squamous cell carcinoma (SCC) and its expression in oral SCC tissues. Immunohistochemical staining revealed that FABP4 expression in the tumor tissue was much higher than that in the non-tumor area of the same specimen. In the in vitro studies, an FABP4-knockdown SCC cell line (established through FABP4-specific siRNA) showed inhibited growth, and inhibited expression and activation of mitogen-activated protein kinase (MAPK). These results indicate that expression of FABP4 plays an important role in the cell growth of oral SCC through the MAPK pathway.

Introduction

Oral squamous cell carcinoma (SCC) is a major neoplasm of the oral cavity with an increasing rate of incidence (13). The optimal therapy for early oral SCC is surgery, but the overall survival rate has exhibited only a slight change (13). Therefore, more effective therapies for oral SCC are needed.

Fatty acid binding proteins (FABPs) are a family of small and highly conserved lipid chaperone molecules that bind long-chain fatty acids and other hydrophobic ligands. Their functions are wide ranging (46). Among them, fatty acid binding protein 4 (FABP4, also known as aP2) is highly expressed in adipocytes, macrophages and dendritic cells (5,7). As a result of its distribution, FABP4 is the most extensively researched FABP in endocrinology and metabolomics. FABP4 affects metabolic syndrome progression; FABP4-deficient mice were found to have reduced hyperinsulinemia and insulin resistance in obesity (7,8) and showed protection from atherosclerosis (9).

However, little is known concerning the role of FABP4 in cancer, including oral SCC. Recently, Nieman et al (10) reported that adipocytes promote ovarian cancer metastasis and tumor cell growth by providing energy mediated by FABP4. Therefore, increased FABP4 expression may affect the growth of various tumor types. Our research group also reported that molecules controlled by peroxisome proliferator-activated receptor γ (PPARγ) play key roles in SCC growth (1115). As FABP4 is known to mediate transcription with PPARγ (4,16), we hypothesized that FABP4 may regulate SCC growth. Therefore, in the present study, we investigated FABP4 expression and its effects on SCC of the tongue.

Materials and methods

Tissue samples

All clinical studies were approved by the Ethics Committee of Osaka University Dental Hospital, Osaka. Twenty-seven SCC specimens from resected tongue tissue were obtained at the Osaka University Dental Hospital during 1986–2008 after patient informed consent (Table I). Patients received no preoperative therapy, including chemotherapy and irradiation therapy. The age range of the patients was 30–92 years (61.6±16.4 years, mean age ± SD); 17 patients were men and 10 were women.

Table I

Characteristics of the patients with squamous cell carcinoma of the tongue, their histological diagnosis and expression of FABP4 in the tissue specimens.

Table I

Characteristics of the patients with squamous cell carcinoma of the tongue, their histological diagnosis and expression of FABP4 in the tissue specimens.

FABP4 expression

Case no.Age (years)GenderDifferentiationTumor areaNon-tumor area
134MaleWell-differentiated SCC10
246FemaleWell-differentiated SCC20
357MaleWell-differentiated SCC11
464MaleWell-differentiated SCC00
569MaleWell-differentiated SCC00
671FemaleWell-differentiated SCC10
771MaleWell-differentiated SCC10
872MaleWell-differentiated SCC20
978FemaleWell-differentiated SCC10
1079MaleWell-differentiated SCC11
1147MaleModerately differentiated SCC10
1261MaleModerately differentiated SCC10
1361FemaleModerately differentiated SCC10
1472MaleModerately differentiated SCC10
1577MaleModerately differentiated SCC12
1683FemaleModerately differentiated SCC32
1792FemaleModerately differentiated SCC10
1830MalePoorly differentiated SCC21
1933MalePoorly differentiated SCC00
2038MalePoorly differentiated SCC00
2151FemalePoorly differentiated SCC00
2252MalePoorly differentiated SCC20
2355FemalePoorly differentiated SCC20
2465MalePoorly differentiated SCC13
2567MalePoorly differentiated SCC32
2641FemaleDifferentiation unknown SCC00
2768FemaleDifferentiation unknown SCC20

[i] Expression of FABP4 by immunohistochemical staining in the tumor and non-tumor areas is scored and expressed as 0–3.

Antibodies

The anti-FABP4 polyclonal antibody was obtained from Bioss Inc. (Woburn, MA, USA). Antibodies against p44/42MAPK and the phosphorylated p44/42MAPK antibody were from Cell Signaling Technology (Beverly, MA, USA).

Immunohistochemical staining and evaluation of FABP4 expression

FABP4 expression in tissues was detected by an anti-FABP4 antibody using standard immunohistochemical techniques (1215). Formalin-fixed and paraffin-embedded continuous sections were selected and sliced into 5-μm sections. Briefly, incubation with an anti-FABP4 polyclonal antibody was performed at 4°C for 16 h; sections were then washed. After applying the secondary antibody, the Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA) was used with a 3,3′-diaminobenzidine substrate kit, according to the manufacturer’s instructions. The staining endpoint was determined when the standard tissue sections were constantly stained at the intensity as previously described (12,17).

The intensity of the immunohistochemical staining with the anti-FABP4 antibody was evaluated by scoring according to four groups: 0, <10%; 1, 10–20%; 2, >20–50%; and 3, >50% of the cells exhibiting cytoplasmic staining (12,17). To confirm the reproducibility, the anti-FABP4 immunohistochemical staining was re-evaluated by a pathologist who was unaware of the original assessment. Non-tumor areas were selected as comparatively normal areas separated from the tumor areas by an appropriate distance and confirmed by the pathologist (14,15).

Cell culture and cell growth assay

We used a human oral SCC cell line (SAS) that was established from tongue SCC (13). Cells were maintained in DMEM containing 10% fetal bovine serum (FBS) at 37°C under 0.5% CO2. For the cell growth experiment, cells were trypsinized and replated onto culture dishes (1115,17,18). SCC cells were counted using a Countess Automated Cell Counter (Invitrogen, Eugene, OR, USA). Inhibition of cell growth was compared with the vehicle-treated controls.

RNA interference approach

The SAS cells were trypsinized and resuspended in DMEM without FBS, and then separated placing ~2×105 cells in each dish. The FABP4-specific siRNA (Stealth siRNA) was purchased from Invitrogen Japan (Tokyo, Japan). We purchased three sequences and performed preparatory experiments to determine the most effective sequence. The sequences of the selected FABP4-siRNA were: sense, 5′-CAC CAUUAAAUCUGAAAGUACCUUU-3′ and antisense, 5′-AAAGGUACUUUCAGAUUUAAUGGUG-3′. For transfection, FABP4-siRNA or a negative control (Stealth RNAi negative control duplex; Invitrogen Japan) solution was added to the DMEM containing Lipofectamine RNAiMax (Invitrogen Japan) and incubated for 20 min at room temperature to create the transfection mixture. The transfection mixture was then added to the cells at the indicated final siRNA concentrations. Following 24 h of transfection, the medium was replaced by DMEM containing 10% FBS, at which time viable cells were counted using a Countess Automated Cell Counter. Cell growth was expressed as a percentage of the vehicle-treated control growth.

Western blot analysis

Adherent or suspended cells were washed in PBS, and the cell extracts were prepared by lysing the cells in lysis buffer. Proteins were separated by electrophoresis using 10% SDS-PAGE and transferred to a nitrocellulose membrane (Millipore, Bedford, MA, USA). Detection of proteins was performed with each polyclonal antibody and visualized using an ECL detection kit (Amersham, London, UK) following the manufacturer’s recommended procedure.

Statistical analysis

Results are expressed as the means ± SEM or ± SD. Statistical comparisons were carried out using the Student’s t-test or the Scheffé’s method after analysis of variance. P<0.05 was considered to indicate a statistically significant result.

Results

Tongue SCC tissues express FABP4

We stained tongue SCC tissues using the FABP4-specific antibody. Within single tumor specimens, the non-tumor areas were unstained (Fig. 1A, upper panel), whereas tumor areas showed positive FABP4 staining (Fig. 1A, lower panel). According to the scoring as described above, FABP4 expression between the non-tumor and the tumor area differed significantly (Fig. 1B), and FABP4 was expressed in the tumor areas, but not in the normal tissues.

FABP4-specific siRNA suppresses the growth of tongue SCC

Treatment with FABP4-siRNA markedly decreased FABP4 protein levels in the SAS cells (Fig. 2A), and suppressed SAS cell growth in a concentration-dependent manner (Fig. 2B). Inhibition of SCC growth was also visibly altered (Fig. 2C), and significantly differed between the SAS controls and the FABP4-knockdown SAS cells (Fig. 2D).

FABP4-specific siRNA inhibits expression and phosphorylation of mitogen-activated protein kinase (MAPK)

To investigate the mechanisms involved in the growth inhibition induced by suppression of FABP4, we analyzed a type of MAPK, serine/threonine protein kinases. Since they affect cell proliferation, survival and differentiation, aberrant MAPK cascades contribute to cancer and other diseases (1921). Therefore, we studied the effects of FABP4 knockdown on MAPK expression and phosphorylation. Western blot analysis showed decreased phosphorylated MAPK (pMAPK; Fig. 3, middle panel). Notably, MAPK expression itself was also regulated by FABP4 knockdown (Fig. 3, upper panel).

Discussion

FABP4 expression has been reported in various types of tumors such as ovarian and bladder cancers (10,22), and FABP5 (E-FAPB) has been found in oral SCC (23,24). However, the expression and exact role of FABP4 in oral SCC have not been widely investigated

In the present study, using an immunohistochemical approach, we consistently found significantly higher expression of FABP4 protein in the tumor area of tongue SCC than in the non-tumor area in the same tissue samples. Therefore, FABP4 expression in tumors may affect SCC cell growth. In fact, we showed that suppression of FABP4 protein by the FABP4-specific siRNA clearly inhibited the growth of SCC cell lines. These results clearly indicate the important role of FABP4 in SCC growth.

FABPs actively facilitate the transport of lipids to specific cellular compartments, including lipid droplets for storage; endoplasmic reticulum for signaling, trafficking and membrane synthesis; mitochondria or peroxisome for oxidation; cytosolic or other enzymes for activity regulation; nuclei for lipid-mediated transcriptional regulation; or even outside the cell for autocrine or paracrine signaling. Among the FABPs, FABP4 is highly expressed in adipocytes, macrophages and dendritic cells and affects these cells in various manners (5). In cancer cells, FABP4 transports energy by carrying fatty acids, encouraging metastasis and tumor cell growth (10). Yet, FABP4 performs other roles in tumor growth, through its various functions. Therefore, we studied the role of FABP4 in the MAPK pathway and the mechanisms of growth inhibition induced by FABP4 suppression.

As the MAPK pathway helps to mediate cell proliferation and cancer growth, it has been widely studied as a potential target for cancer therapy (1921). In fact, our present research showed decreased MAPK expression and phosphorylation 12 h following treatment with FABP4-specific siRNA, which indicates that FABP4 affects cell growth through the MAPK pathway. Notably, expression of MAPK itself was also suppressed by FABP4 knockdown; FABP4 may affect transcription of MAPK, which implies a complex role for FABP4 in tumor growth. Inhibition of the MAPK pathway may be one of the several mechanisms through which FABP4 mediates tumor growth (Fig. 4). Further investigation is warranted.

In the present study, FABP4 expression in the tumor tissues was not correlated with age, gender, histological tumor differentiation or survival rate of the cases. Of our 27 cases, 12 had neck lymph node metastasis, all 12 of whom showed FABP4 expression in lymph nodes, similar to that in the primary tumors (data not shown). Thus, FABP4 expression may affect metastasis to neck lymph nodes; this role merits further investigation.

In summary, we demonstrated FABP4 expression in human tongue SCC tissues and cultured SCC cells. Our results suggest an important role for FABP4 in SCC growth and indicate that FABP4 is a potential target for the therapy of oral SCC.

Acknowledgements

The present study was supported in part by grants (T245928310 to Y.T.) from the Japanese Society for the Promotion of Science.

References

1 

Prince S and Bailey BM: Squamous carcinoma of the tongue: review. Br J Oral Maxillofac Surg. 37:164–174. 1999. View Article : Google Scholar : PubMed/NCBI

2 

Okura M, Hiranuma T, Adachi T, et al: Induction chemotherapy is associated with an increase in the incidence of locoregional recurrence in patients with carcinoma of the oral cavity: results from a single institution. Cancer. 82:804–815. 1998. View Article : Google Scholar : PubMed/NCBI

3 

Goepfert H: Squamous cell carcinoma of the head and neck: past progress and future promise. CA Cancer J Clin. 48:195–198. 1998. View Article : Google Scholar : PubMed/NCBI

4 

Schroeder F, Petrescu AD, Huang H, et al: Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. Lipids. 43:1–17. 2008. View Article : Google Scholar : PubMed/NCBI

5 

Furuhashi M and Hotamisligil GS: Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 7:489–503. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Storch J and Thumser AE: The fatty acid transport function of fatty acid-binding proteins. Biochim Biophys Acta. 1486:28–44. 2000. View Article : Google Scholar : PubMed/NCBI

7 

Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE and Spiegelman BM: Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 274:1377–1379. 1996. View Article : Google Scholar : PubMed/NCBI

8 

Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S and Hotamisligil GS: Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology. 141:3388–3396. 2000. View Article : Google Scholar : PubMed/NCBI

9 

Makowski L, Boord JB, Maeda K, et al: Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 7:699–705. 2001. View Article : Google Scholar : PubMed/NCBI

10 

Nieman KM, Kenny HA, Penicka CV, et al: Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 17:1498–1503. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Masuda T, Wada K, Nakajima A, et al: Critical role of peroxisome proliferator-activated receptor γ on anoikis and invasion of squamous cell carcinoma. Clin Cancer Res. 11:4012–4021. 2005.

12 

Nagata M, Wada K, Nakajima A, et al: Role of myeloid cell leukemia-1 in cell growth of squamous cell carcinoma. J Pharmacol Sci. 110:344–353. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Kusayama M, Wada K, Nagata M, et al: Critical role of aquaporin 3 on growth of human esophageal and oral squamous cell carcinoma. Cancer Sci. 102:1128–1136. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Ishimoto S, Wada K, Tanaka N, et al: Role of endothelin receptor signalling in squamous cell carcinoma. Int J Oncol. 40:1011–1019. 2012.PubMed/NCBI

15 

Ishimoto S, Wada K, Usami Y, et al: Differential expression of aquaporin 5 and aquaporin 3 in squamous cell carcinoma and adenoid cystic carcinoma. Int J Oncol. 41:67–75. 2012.PubMed/NCBI

16 

Tan NS, Shaw NS, Vinckenbosch N, et al: Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol. 22:5114–5127. 2002. View Article : Google Scholar

17 

Ishida H, Wada K, Masuda T, et al: Critical role of estrogen receptor on anoikis and invasion of squamous cell carcinoma. Cancer Sci. 98:636–643. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Takahashi H, Fujita K, Fujisawa T, et al: Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties. Cancer Sci. 97:854–860. 2006. View Article : Google Scholar

19 

Roux PP and Blenis J: ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 68:320–344. 2004. View Article : Google Scholar : PubMed/NCBI

20 

Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI

21 

Santarpia L, Lippman SM and El-Naggar AK: Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Boiteux G, Lascombe I, Roche E, et al: A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer. 124:1820–1828. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Uma RS, Naresh KN, D’Cruz AK, Mulherkar R and Borges AM: Metastasis of squamous cell carcinoma of the oral tongue is associated with down-regulation of epidermal fatty acid binding protein (E-FABP). Oral Oncol. 43:27–32. 2007. View Article : Google Scholar : PubMed/NCBI

24 

Fang LY, Wong TY, Chiang WF and Chen YL: Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. J Oral Pathol Med. 39:342–348. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

2014-March
Volume 31 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lee D, Wada K, Taniguchi Y, Al-Shareef H, Masuda T, Usami Y, Aikawa T, Okura M, Kamisaki Y, Kogo M, Kogo M, et al: Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma. Oncol Rep 31: 1116-1120, 2014.
APA
Lee, D., Wada, K., Taniguchi, Y., Al-Shareef, H., Masuda, T., Usami, Y. ... Kogo, M. (2014). Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma. Oncology Reports, 31, 1116-1120. https://doi.org/10.3892/or.2014.2975
MLA
Lee, D., Wada, K., Taniguchi, Y., Al-Shareef, H., Masuda, T., Usami, Y., Aikawa, T., Okura, M., Kamisaki, Y., Kogo, M."Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma". Oncology Reports 31.3 (2014): 1116-1120.
Chicago
Lee, D., Wada, K., Taniguchi, Y., Al-Shareef, H., Masuda, T., Usami, Y., Aikawa, T., Okura, M., Kamisaki, Y., Kogo, M."Expression of fatty acid binding protein 4 is involved in the cell growth of oral squamous cell carcinoma". Oncology Reports 31, no. 3 (2014): 1116-1120. https://doi.org/10.3892/or.2014.2975